Effect of Home Based Pulmonary Rehabilitation on Exacerbation and Hospital Admission in Severe COPD
Launched by SAGLIK BILIMLERI UNIVERSITESI · Feb 12, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a home-based pulmonary rehabilitation program for people with severe Chronic Obstructive Pulmonary Disease (COPD). The aim is to see if this program can help reduce the number of times patients experience worsening symptoms, known as exacerbations, and if it can lower the chances of needing to go to the hospital. Participants will be divided into two groups: one will use a home spirometer, a device that helps measure breathing, and the other will not. Both groups will do breathing and exercise activities, and their progress will be checked over a year.
To join the trial, participants should be between 18 and 75 years old, diagnosed with severe COPD (stages C and D), and able to perform daily activities without recent infections or flare-ups. They should also be comfortable using a smartphone and the spirometer after receiving training. Throughout the trial, participants can expect to have their exercise ability, muscle strength, and symptoms assessed at different times. It's important to note that individuals with certain serious health issues or those who have participated in similar rehabilitation programs recently will not be eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being between the ages of 18-75
- • Having a diagnosis of COPD stages C and D diagnosed according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) clinical diagnostic criteria
- • Presence of dyspnea on exertion
- • Stable clinical condition at the time of inclusion without infection or exacerbation in the previous 4 weeks
- • Having the ability to use a smart phone and spirometer after training
- Exclusion Criteria:
- • Patients with severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases and needing high flow oxygen therapy (˃ 3-4 L \\min).
- • A history of effort-related syncope or any comorbidity (such as severe orthopedic or neurological deficits or unstable heart disease) that precludes exercise training.
- • Participation in a pulmonary rehabilitation program within the past 12 months.
About Saglik Bilimleri Universitesi
Saglik Bilimleri Universitesi, or the University of Health Sciences, is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university focuses on translating scientific discoveries into practical applications that enhance patient care and public health outcomes. Its commitment to rigorous ethical standards and comprehensive training equips researchers and healthcare professionals to contribute effectively to the global medical community. Through its clinical trial initiatives, Saglik Bilimleri Universitesi aims to address pressing health challenges and foster the development of new therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Esra PEHLİVAN, Assoc. Prof.
Principal Investigator
Saglik Bilimleri Universitesi
Erdoğan ÇETİNKAYA, Prof. Dr.
Study Director
Saglik Bilimleri Universitesi
Mustafa ÇÖRTÜK, Assoc. Prof.
Study Chair
SBU Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital
Fulya Senem KARAAHMETOĞLU, M. Sc.
Study Chair
Saglik Bilimleri Universitesi
Zeynep Betül ÖZCAN, M. Sc.
Study Chair
Saglik Bilimleri Universitesi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials